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IFI16, member of the IFN-inducible PYHIN-200 gene family, modulates proliferation, survival and differentiation
of different cell lineages. In particular, IFI16 expression, which is regulated during the differentiation of B cells,
was recently studied in B-CLL as well. Here, we compared IFI16 expression in several lymphomas including
Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma and mantle cell
lymphoma with respect to normal cell counterparts. We observed that IFI16 expression was significantly
deregulated only in mantle cell lymphoma (p < 0.05). Notably, IFI16 was associated with the expression of genes
involved in interferon response, cell cycle, cell death and proliferation and, interestingly, lipid and glucose
metabolism, suggesting that IFI16 deregulation might be associated with relevant changes in cell biology. In our
group of mantle cell lymphoma samples a correlation between patient survival and IFI16 expression was not
detected even though mantle cell lymphoma prognosis is known to be associated with cell proliferation. Alto-
gether, these results suggest a complex relationship between IFI16 expression and MCL which needs to be
analyzed in further studies.1. Introduction
IFI16 belongs to the IFN-inducible PYHIN-200 gene family [1, 2]
encoding evolutionary related proteins that share a 200-amino acid
signature motif (hematopoietic interferon-inducible nuclear, HIN). IFI16
displays two HIN domains separated by a spacer region the length of
which is the result of an alternative mRNA splicing leading to the pro-
duction of three IFI16 isoforms (A, the predominant isoform; B and C; 3)
detectable in several cell types [1]. IFI16 protein localizes both in nucleus
and cytoplasm and it is able to either homodimerize or heterodimerize
with different partners including BRCA1, TP53, ASC, RB and STING [3, 4,.P. Piccaluga).
orm 12 July 2019; Accepted 9 O
evier Ltd. This is an open access a5, 6, 7, 8]. It is noteworthy that IFI16 binds dsDNA sugar phosphate
backbone through its positive charged residues in the HIN domain [9,
10]. Several reports indicated that IFI16 can be considered a DNA sensor
involved both in the innate immune response, in particular against viral
infections, including HSV-1, HCMV and HIV-1 [11, 12, 13, 14, 15, 16, 17]
and in the activation of the interferon gene pathway. Indeed, IFI16 is
required for the cGAMP-induced activation of STING, promoting its
phosphorylation and translocation [18]. IFI16 and cGAS are involved in
the activation of the innate immune response to infections by DNA vi-
ruses [6, 16]. The biological role of IFI16 in the cellular biology has been
demonstrated by several studies showing that IFI16 regulatesctober 2019
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Fig. 1. IFI16 gene expression in lymphoma subtypes. Five NHL tumors were compared with their normal counterparts in terms of IFI16 expression, among which
only MCL showed altered expression of IFI16.
P.P. Piccaluga et al. Heliyon 5 (2019) e02643proliferation, differentiation, apoptosis/pyroptosis, senescence and
inflammation [19, 20, 21, 22, 23, 24, 25, 26]. More specifically, IFI16 has
been shown to down-regulate cell proliferation and to elicit apoptosis in
several cell types [21, 23, 26]. Consistently, IFI16 negatively regulates
the cell cycle through binding and functional modulation of several
molecules involved in the cell cycle regulation such as TP53, RB, and p21
[21, 25, 26]. The relationship between IFI16 and differentiation wasFig. 2. IFI16 expression in validation cohorts. A) IFI16 gene expression in MCL.
negative and b) weak positive for IFI16 expression; c) follicular lymphoma, d) marg
showing strong expression for IFI16.
2pointed out during the differentiation of CD34 þ hematopoietic stem
cells to lymphoid and monocytic lineages [1, 27]. Furthermore, recent
studies have shown that IFI16 expression is modulated in B-cell differ-
entiation [28]. In particular, IFI16 expression is related to B-cell differ-
entiation stages and it is significantly downregulated during both the
transition from naive B-cell subsets to proliferating GC cells and the
differentiation of GC-cells to plasma cells, whereas IFI16 expressionB) IFI16 protein expression at immunohistochemistry: mantle cell lymphoma a)
inal zone lymphoma, e) diffuse large B-cell lymphoma and f) Burkitt lymphoma
Fig. 3. Association of IFI16 expression with other genes and specific cellular functions. In A, Hierarchical clustering of MCL and normal B cells (Naive and
memory) based on the expression of genes the expression of which is significantly related to that of IFI16 (Pearson correlation >0.5) is depicted. In Panel B–E, GSEA
indicative of metabolic reprogramming in cases with reduced IFI16 expression is presented.
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expression is believed to have an intriguing relationship with key tran-
scription factors, including BCL6, NF-κB, STAT3, and STAT5, involved in
central processes of the B-cell biology [28, 29]. Interestingly, gene
expression profiling analysis showed that IFI16 expression was inversely
related to the expression of the transcription factor BCL6, a master
regulator of GC constitution [28, 29]. IFI16 was also studied as prog-
nostic biomarkers in chronic lymphocytic leukemia (CLL) patients.
Interestingly, reduced IFI16 expression was linked to a worse clinical
outcome when ZAP70 and CD38 molecules were expressed. Probably,
the lack of IFI16, associated with an abridged antiproliferative effect,
might be particularly severe in cells constitutively receiving an activa-
tion/proliferation signaling. Therefore, the balance between IFI16
expression and activation signaling (mediated by ZAP70/CD38) may be a
more reliable prognostic parameter [30].Table 1
Descriptive statistics for IFI16 gene expression in lymphoma subtypes.
Count Mean Std. Dev Std. Err.
Burkitt lymphoma 46 -0.146 0.617 0.091
Diffuse large B-cell lymphoma/NOS 46 -0.19 0.448 0.066
Follicular lymphoma 40 0.104 0.306 0.048
Mantle cell lymphoma (training set) 22 0.123 0.595 0.127
Mantle cell lymphoma (validation set) 64 -0.375 0.766 0.096
Marginal zone lymphoma 24 0.472 0.456 0.093
Germinal center B-cells 10 0.102 0.251 0.079
Memory B-cells 5 0.498 0.242 0.108
Naïve B-cells 5 0.544 0.074 0.033
3In this study, we aimed to assess the expression of IFI16 at gene and
protein levels in a large series of B-cell derived non-Hodgkin lymphomas
(NHLs), aiming to assess IFI16 expression as a possible prognostic marker
in these NHLs.
2. Materials and methods
2.1. Case series
We studied the expression of IFI16 gene in a discovery cohort of 198
cases for which gene expression profiles (GEPs) were previously gener-
ated (GSE12195) [31]. This data is available on GEO Profiles database
(Gene Expression Omnibus of the National Center for Biotechnology
Information-NCBI) which stores gene expression profiles derived fromTable 2
Immunohistochemical evaluation of IFI16 protein expression.
Lymphoma type Number of
cases
Positive cases (>20%
cells) (%)
Staining
intensity grade
Burkitt lymphoma 11 8 (72.7) Strong
Diffuse large B-cell
lymphoma
26 15 (57.7) Strong
Follicular lymphoma 24 8 (33.3) Strong/Weak*
Mantle cell
lymphoma
32 19 (59.4) Weak
Marginal zone
lymphoma
13 4 (30.8) Strong
* 4 cases regular; 4 cases reduced.
Table 3
Genes whose expression is significantly related to that of IFI16 (Pearson corre-
lation >0.5).
Gene Symbol Entrez Gene Pearson
correlation
Validated expression
in MCL
ACTR2 10097 0,669208933
ANP32E 81611 0,627841533
ARF6 382 0,641927687
BANK1 55024 0,67225964
BAZ1A 11177 0,630230747
BBIP1 92482 0,605706487
BCL11A 53335 0,569828467 Liu H et al.,2006
BCLAF1 9774 0,68433418
BLOC1S2 282991 0,6491966
CD22 933 0,618896733 Jovanovic D et al.,
2014
CDC42 998 0,576680253
CEP350 9857 0,617435543
CNOT6L 246175 0,58337405
COLCA1 399948 0,616912253
CTSS 1520 0,638810313 Magunacelaya NM
et al.,2004
DAPP1 27071 0,635009267
DDI2 84301 0,571980767
DEGS1 8560 0,574676047
DICER1 23405 0,592437383
DNAJA2 10294 0,648920167
EIF3M 10480 0,560212283
EIF4G3 8672 0,573264233
ERBB2IP 55914 0,70120698
FGD2 221472 0,607602133 Norihiko Kawamata
et al., 2005
FGD2 221472 0,586247077 Norihiko Kawamata
et al., 2005
GNAI3 2773 0,595270897
GPR18 2841 0,542490437 Henson SE, 2011 and
Zhu et al., 2001
GVINP1 387751 0,6061212
HHEX 3087 0,61690237 Nagel S et al., 2018
HHEX 3087 0,559629767 Nagel S et al., 2018
HNRNPU 3192 0,679190433
IAH1 285148 0,682675547
IFNGR1 3459 0,610652857
IL10RB 3588 0,61914352
KIAA0922 23240 0,610119713
KIAA1551 55196 0,620209807
KRAS 3845 0,601086023
LNPEP 4012 0,633301233
MGAT2 4247 0,564773553
MOB1A 55233 0,565978067
NCOA3 8202 0,66112306
NCOA3 8202 0,631385923
NIFK 84365 0,628177233
NIPBL 25836 0,682132577
NUDT4///
NUDT4P1///
NUDT4P2
11163///
170688///
440672
0,55685546
OPHN1 4983 0,576196457
P2RY10 27334 0,647883497
P2RY10 27334 0,606733317
PDIA6 10130 0,549549553
PGGT1B 5229 0,6341306
PPP1CB 5500 0,618264833 Velusamy et al.,2013
PRKD3 23683 0,562186867
PRPS2 5634 0,680414633
PRRC2C 23215 0,66378871
PRRC2C 23215 0,6341602
PRRC2C 23215 0,625491777
PTP4A2 8073 0,60902381
PTPRC 5788 0,644289767 Carulli G et al., 2008
RAPGEF6 51735 0,578388253
RASEF 158158 0,60727635
RHOQ 23433 0,699054647
RHOQ 23433 0,630388733
RHOQ 23433 0,573807233
RIOK3 8780 0,603100097
RPL38 6169 0,553390113
Table 3 (continued )
Gene Symbol Entrez Gene Pearson
correlation
Validated expression
in MCL
SAMD9 54809 0,54420831
SCAF11 9169 0,577746523
SEC22B 9554 0,699726023
SLC25A16 8034 0,6782821
SNX2 6643 0,610563997
SNX5 27131 0,66154758
SP110 3431 0,61964704
SP110 3431 0,608826357
SRSF10 10772 0,651625337
ST8SIA4 7903 0,587273833
STK4 6789 0,63018144
SUMO4 387082 0,64389485
TMED8 283578 0,660115983
TOR1AIP1 26092 0,617741593
TRAK2 66008 0,628364817
TRIM38 10475 0,6677971
TRIM38 10475 0,635720103
UBXN4 23190 0,6740565
UBXN7 26043 0,5930396
WSB1 26118 0,633321007
WTAP 9589 0,676307537
YWHAZ 7534 0,61512527
ZC3H7B 23264 0,53514501
ZNF106 64397 0,612370733
ZNF207 7756 0,586681463
ZNF430 80264 0,631612967
ZNF652 22834 0,61678393
ZNF665 79788 0,6342984
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4curated GEO DataSets. Specifically, we analyzed 46 Burkitt lymphoma
(BL), 46 diffuse large B-cell lymphoma (DLBCL), 40 follicular lymphoma
(FL), 24 marginal zone lymphoma (MZL), and 22 mantle cell lymphoma
(MCL) cases. Furthermore, 20 samples representative of normal B-cell
subsets (10 germinal center, GC, 5 naïve, and 5 memory) were also
analyzed. In addition, we studied a validation cohort of cases including
86 MCL cases for which GEP were available at the NCBI GEO database
(Accession Numbers: GSE21452 and GSE16455) as well as 106 cases for
which formalin fixed paraffin embedded (FFPE) tissue blocks were
retrieved at the Hematopathology Unit of S. Orsola-Malpighi Hospital,
Bologna University, Bologna, Italy, and used for histopatological exam-
ination. The latter cases included 11 BL, 26 DLBCL, 24 FL, 13 MZL, and
32 MCL. All diagnoses were made according to the World Health Orga-
nization (WHO) classification.
2.2. Immunohistochemistry on tissue microarrays
A Giemsa-stained slide was prepared from each paraffin block con-
taining representative tumor regions marked on every slide. Tissue cyl-
inders with a diameter of 1.0 mm were punched from the marked areas
on each block and placed in a recipient paraffin block using a precision
instrument as previously described [28, 30]. Punches were performed on
areas mainly represented by neoplastic cells based on morphological and
immunophenotypic evaluation. Tissue microarrays (TMAs) were then
prepared for immunohistochemistry.
We studied IFI16 expression by immunohistochemistry (IHC) on
TMAs including 32 cases (in duplicate cores). From each recipient block,
1.5 μm-thick sections were cut and tested with anti-IFI16 mouse mono-
clonal antibody (Sigma, Milan, Italy, dilution 1:100). Briefly, paraffin-
embedded sections were dewaxed and submitted to antigen retrieval
by heating in Dako PTLink (DakoCytomation, Glostrup, Denmark; code
PT100/PT101) in an EnVision Flex Target Retrieval Solution High pH
(DakoCytomation; code K8004) at 92 C for 5 min. Sections were incu-
bated at room temperature with fetal calf serum (10 min) and then with
the specific primary antibody (for 30 min). Each evaluation was per-
formed by at least two expert hematopathologists blinded to the study.
Scores were compared and consensus agreement was reached at the
microscope in all cases.
Table 4
Gene set enrichment analysis of genes related to IFI16.
Gene set category Gene Set Name # Genes in Gene Set
(K)
# Genes in Overlap
(k)
k/K p-value FDR q-
value
Hallmark ALLOGRAFT REJECTION 200 6 0,03 1,25E-
06
3,12E-05
INTERFERON GAMMA RESPONSE 200 6 0,03 1,25E-
06
3,12E-05
MITOTIC SPINDLE 200 4 0,02 3,86E-
04
6,43E-03
PROTEIN SECRETION 96 3 0,0312 6,00E-
04
7,50E-03
Gene Ontology Biological
Process
CELLULAR MACROMOLECULE LOCALIZATION 1234 15 0,0122 2,25E-
09
1,33E-05
PROTEIN LOCALIZATION 1805 17 0,0094 7,54E-
09
2,23E-05
ESTABLISHMENT OF LOCALIZATION IN CELL 1676 16 0,0095 1,85E-
08
3,65E-05
CELL SUBSTRATE JUNCTION 398 9 0,0226 2,70E-
08
3,99E-05
CYTOSKELETON ORGANIZATION 838 11 0,0131 1,78E-
07
2,11E-04
CELL PROJECTION ORGANIZATION 902 11 0,0122 3,68E-
07
3,63E-04
RIBONUCLEOTIDE BINDING 1860 15 0,0081 4,78E-
07
4,04E-04
ESTABLISHMENT OF PROTEIN LOCALIZATION 1423 13 0,0091 7,75E-
07
5,63E-04
EARLY ENDOSOME 301 7 0,0233 8,56E-
07
5,63E-04
POSTTRANSCRIPTIONAL REGULATION OF GENE
EXPRESSION
448 8 0,0179 9,90E-
07
5,86E-04
P.P. Piccaluga et al. Heliyon 5 (2019) e02643Immunohistochemistry staining was scored based on the percentage
of positive neoplastic cells (visual count performed by two hema-
topathologists) as follows: 0¼ no positive cells; 1¼ 1–20%; 2¼ 21–40%;
3 ¼ 41–60%; 4 ¼ 61–80%; and 5 ¼ 81–100%. A Semi-quantitative
scoring system was used to assess staining intensity and graded as
“strong”, “weak”, and “absent” [32].
Micrographs were obtained using an Olympus BX61 microscope
equipped with an Olympus DP-70 digital camera. Image acquisition,
evaluation and color balance were performed using by Cell^F software
[28, 30].
2.3. Gene expression analyses
Gene expression analysis was carried out as previously reported [31,
33, 34, 35, 36, 37, 38]. Analysis of GEP data in terms of supervised and
unsupervised analysis was achieved using GeneSpring GX 12 (Agilent
Technologies, Santa Clara, CA, USA). All data were obtained using
Affymetrix HG-U133 2.0 plus microarrays (Affymetrix, Inc. http:
//www.affymetrix.com/support/index.affx). Briefly, the expression
value of each selected gene was normalized to have a zero mean value
and unit standard deviation. The distance between two individual sam-
ples was determined by Pearson correlation using the normalized
expression values. Unsupervised clustering was generated using a hier-
archical algorithm based on the average-linkage method. To perform the
supervised gene expression analysis, differentially expressed genes be-
tween different groups were identified using a two-tails Student t-test and
adjusted Benjamini-Hochberg correction for false discovery rate,
applying the following filtering criteria: p-value 0.05, and fold change
2.
Gene Set Enrichment Analysis (GSEA) was performed to better un-
derstand the potential biological significance of the identified molecular
signatures. Briefly, GSEA (also known as functional enrichment analysis) is
a method to identify classes of genes that are over-represented in a large
set of genes (molecular or gene signature) and may have a functional
association with disease phenotypes [39]. GSEA of the interested gene
sets was performed in terms of Gene Ontology (GO) Biological Processes,
Curated Gene Sets and Hallmark Genes using GSEA MsigDB (www5.broadinstitute.org/gsea/msigdb) web-based analysis tool [39], setting
the options to the default (displaying top 10 gene sets with FDR q-value
below 0.05).
When we focused our analysis on IFI16 expression, we identified
IFI16 expression using three different probe sets (206332_s_at;
208966_x_at; and 208965_s_at) in the HG-U133 2.0 plus microarray. The
median value from the three probes was used for the analysis.
2.4. Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics 20.0
and Prism (GraphPad softwares, USA). ANOVA and unpaired T-tests were
employed.When a sample size was less than 10 cases in at least 1 group, a
non-parametric (Mann-Whitney) test was used to analyze the GEP data to
compare IFI16 expression in different subgroups. Survival analyses were
performed by Kaplan-Meier method. Two-sided tests were used in all
calculations. The limit of significance for all analyses was defined as p 
0.05.
3. Results and discussion
3.1. IFI16 gene expression is reduced in mantle cell lymphoma
We studied IFI16 gene expression in the cohort of lymphoma cases,
including 46 BL, 46 DLBCL, 40 FL, 24 MZL, and 22 MCL cases (Fig. 1A).
Particularly, we compared gene expression between each tumor type and
the corresponding cellular counterpart (i.e. GC cells for BL, FL, and
DLBCL and Naïve and/or Memory B-cells for MCL and MZL). Only MCL
showed a significant deregulation when compared to the non-neoplastic
components (0.123 vs. 0.525; standard error 0.127 vs. 0.059, p ¼ 0.047;
Fig. 1B–F, Table 1). It should be noted that MCL were compared to both
naïve and memory B-cell compartments that represent the postulated
counterparts of unmutated and mutated MCL cases, respectively. Since
our cases were not distinct based on the immunoglobulin mutational
status, naïve/memory subsets have comparable levels of IFI16 [28], and
IFI16 is not differentially expressed in mutated vs. unmutated MCL cases
[40], we were confident that this approach could be considered reliable.
Table 5
Gene differentially expressed in cases with higher (75 percentile) vs. lower (25
percentile) IFI16 gene expression (T-test, p < 0.05; fold change >2).
Probe Set ID Gene Symbol Corrected
pvalue
FC
(absolute)
Regulation
in Low
229128_s_at ANP32E 0,002372331 2,6861453 Down
209642_at BUB1 0,012277976 2,1282046 Down
231862_at CBX5 0,001654886 2,0196693 Down
208711_s_at CCND1 0,004513383 2,067266 Down
205789_at CD1D 0,004146486 2,0740635 Down
224428_s_at CDCA7 0,003771309 2,0563602 Down
219375_at CEPT1 1,66E-04 2,099846 Down
213060_s_at CHI3L2 0,00131052 2,8916368 Down
230128_at CKAP2 0,015628582 3,0252607 Down
203641_s_at COBLL1 0,007359529 2,1361105 Down
203642_s_at COBLL1 0,005629572 2,5396304 Down
1562836_at DDX6 0,02511044 2,0845397 Down
212503_s_at DIP2C 9,26E-04 2,212788 Down
222850_s_at DNAJB14 0,005629572 2,0553403 Down
219990_at E2F8 0,017218044 2,1936398 Down
1555996_s_at EIF4A2 0,028180348 2,023231 Down
206102_at GINS1 0,001741233 2,1084065 Down
221922_at GPSM2 0,002576029 2,0255637 Down
220085_at HELLS 0,003709542 2,3137715 Down
200679_x_at HMGB1 4,27E-04 2,002743 Down
230621_at IAH1 1,53E-04 2,028879 Down
206332_s_at IFI16 2,07E-10 2,352239 Down
208965_s_at IFI16 8,91E-04 2,1735976 Down
208966_x_at IFI16 3,93E-10 2,4121406 Down
203819_s_at IGF2BP3 0,008682512 4,002813 Down
203820_s_at IGF2BP3 0,010148156 4,122018 Down
223176_at KCTD20 0,0013064 2,0591123 Down
227152_at KIAA1551 0,00707586 2,0117857 Down
210313_at LILRA4 0,022168344 2,321087 Down
235060_at LOC100190986 0,001798373 2,1002595 Down
235167_at LOC100190986 0,009055208 2,0777555 Down
229026_at LOC105379173 0,020182207 2,4816926 Down
230793_at LRRC16A 0,002684468 2,303797 Down
201151_s_at MBNL1 0,020108812 2,033717 Down
222036_s_at MCM4 4,09E-04 2,1149127 Down
226880_at NUCKS1 1,65E-04 2,667727 Down
223381_at NUF2 0,003363432 2,2747343 Down
219148_at PBK 0,014257969 2,133363 Down
201202_at PCNA 2,63E-04 2,0165021 Down
212094_at PEG10 0,021157807 2,0085702 Down
204285_s_at PMAIP1 0,002559309 2,0691586 Down
230352_at PRPS2 6,56E-05 2,2383318 Down
228273_at PRR11 0,011947047 2,3246174 Down
229147_at RASSF6 0,009268034 3,8838599 Down
233463_at RASSF6 0,003219189 2,6172767 Down
235638_at RASSF6 0,007068038 2,7792645 Down
228455_at RBM15 0,002473682 2,485874 Down
212027_at RBM25 0,005629572 2,0230834 Down
228996_at RC3H1 8,88E-04 2,6803448 Down
214257_s_at SEC22B 1,24E-04 2,0202684 Down
221268_s_at SGPP1 0,033115014 2,0768883 Down
223391_at SGPP1 0,01181035 2,085591 Down
206108_s_at SRSF6 0,002559309 2,4004695 Down
209754_s_at TMPO 0,010170757 2,312462 Down
223949_at TMPRSS3 0,02754625 2,1164422 Down
201291_s_at TOP2A 0,028759345 2,3533485 Down
228588_s_at UBE2B 4,92E-04 2,2184792 Down
235003_at UHMK1 0,002675724 2,2043898 Down
206133_at XAF1 0,017114462 2,0860553 Down
222816_s_at ZCCHC2 0,002387533 2,2362235 Down
205739_x_at ZNF107 0,00147799 2,0554366 Down
243495_s_at ZNF652 0,002730198 2,3722727 Down
236033_at ASB12 1,58E-04 2,0688426 Up
1552354_at CBARP 1,66E-04 2,162268 Up
201289_at CYR61 0,027891243 2,8001204 Up
210764_s_at CYR61 0,035330884 2,2227159 Up
1565483_at EGFR 9,60E-05 4,008361 Up
1565484_x_at EGFR 1,58E-04 2,8769505 Up
1564069_at HOTTIP 1,74E-04 2,0109012 Up
1553657_at LOC101930115///
VWA3A
9,50E-05 2,086649 Up
1559502_s_at LRRC25 1,37E-04 2,1343188 Up
Table 5 (continued )
Probe Set ID Gene Symbol Corrected
pvalue
FC
(absolute)
Regulation
in Low
230813_at P3H2 3,33E-04 2,3854458 Up
1557680_at SAMD15 3,33E-04 2,2336347 Up
1568249_at SNHG17///
SNORA71B
1,97E-04 2,6449728 Up
1558641_at SPATA24 5,49E-04 2,0069237 Up
1569206_at TCP11L2 8,09E-05 2,2803137 Up
1554400_at TCTE3 1,26E-04 2,482754 Up
1557450_s_at WHAMMP2 3,17E-04 2,0680783 Up
1553718_at ZNF548 2,81E-04 2,12732 Up
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6A trend toward a reduced expression was also observed in DLBCL;
however, the difference was not significant (p ¼ 0.07). Of note, DLBCL
were compared to GC only, GEP from plasmablasts, the postulated
counterpart of ABC-type DLBCL not being available. Nonetheless, this
choice did not seem to affect the analysis since ABC and GCB-type DLBCL
did not show differential IFI16 gene expression [41].
Thereafter, we studied IFI16 expression in a validation cohort of
cases. When IFI16 gene expression levels were studied in 64 MCL vs.
naïve (N ¼ 5) and memory (N ¼ 5) B-cell samples, an even more evident
difference was observed (-0.375 vs. 0.498 vs. 0.544, ANOVA, p-value ¼
0.002; Fig. 2A). In fact, again, IFI16 expression levels were higher than in
memory (p ¼ 0.01) and naïve (p ¼ 0.009) B-cell subtypes.
To improve the strength of these data, we also studied IFI16 protein
expression by immunohistochemistry in a series consisting of 11 BL, 26
DLBCL, 24 FL, 13 MZL, and 32 MCL. We found a variable degree of
expression with positive cases ranging from 31% in MZL to 73% in BL.
Concerning MCL, 19/32 cases were positive (59%). Noteworthy, the
intensity of the staining was strong in all positive cases with the excep-
tion of all MCL and a few FL, in which the staining was weak (Fig. 2B;
Table 2). A similar pattern has also been observed in chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL), the first lymphoid
neoplasm in which a weak IFI16 expression was documented [30].
Overall, these data indicate that MCL significantly down-regulates IFI16,
even in cases that do not completely abolish its expression.3.2. IFI16 gene down-regulation is associated with increased proliferation
and altered metabolism in MCL
We sought to assess whether the expression of IFI16 was associated
with the expression of other genes and specific cellular functions. To do
so, we studied the transcriptome of B-NHL and normal B-cell subsets,
looking for genes with expression levels correlated to those of IFI16. We
found 93 genes whose expressionwas significantly related to that of IFI16
(Pearson correlation >0.5; Fig. 3A; Table 3). Interestingly, at GSEA, they
turned out to be significantly involved in interferon response and allo-
graft rejection (as expected based on IFI16 known functions), as well as in
other biological processes (Table 4). Of interest, these findings were, at
least in part, validated by the evidence that several of the identified
molecules are indeed expressed in MCL, showing sometimes a reduced
expression mirroring that of IFI16, including CD22, BCL11A, FGD2,
GPR18, PTPRC, HHEX, PPP1CB, and CTSS [42, 43, 44, 45, 46, 47].
We then compared the cases with the highest (25th percentile) or
lowest (25th percentile) IFI16 gene expression with supervised anal-
ysis. We found 79 genes differentially expressed in the two groups
(Table 5); by GSEA they turned out to be significantly involved in cell
cycle, cell death and proliferation as well as in other programs
(Table 6). Furthermore, GSEA indicated that the two groups signifi-
cantly differed as far as certain biological processes related to meta-
bolism were concerned. Particularly, both lipid and glucose
metabolism appeared affected (Fig. 3B–E; Table 6). Overall, these data
indicated that IFI16 deregulation was associated with relevant changes
in cell biology.
Table 6
Gene set enrichment analysis of genes differentially expressed in cases (referred
to Gene Ontology Biological Process gene sets).
Gene Set Name p-value FDR q-
value
GO LIPID DIGESTION 0 1
GO RESPIRATORY SYSTEM PROCESS 0 0,981
GO REGULATION OF SYNCYTIUM FORMATION BY
PLASMA MEMBRANE FUSION
0 1
GO REGULATION OF MYOBLAST FUSION 0 0,737
GO RESPONSE TO MAGNESIUM ION 0 0,691
GO HYPEROSMOTIC RESPONSE 0 0,893
GO MONOCARBOXYLIC ACID TRANSMEMBRANE
TRANSPORTER ACTIVITY
0 1
GO SYNAPTIC VESICLE LOCALIZATION 0 1
GO MITOTIC CELL CYCLE 4,26E-
10
1,89E-06
GO CELL PROLIFERATION 1,56E-
09
2,08E-06
GO CELL CYCLE PROCESS 1,80E-
09
2,08E-06
GO CELL CYCLE 1,88E-
09
2,08E-06
GO CELL DEATH 8,49E-
09
7,53E-06
GO RESPONSE TO UV 2,04E-
08
1,51E-05
GO POSITIVE REGULATION OF DNAMETABOLIC PROCESS 2,00E-
07
1,27E-04
GO NEGATIVE REGULATION OF NITROGEN COMPOUND
METABOLIC PROCESS
7,52E-
07
4,17E-04
GO CHROMOSOME ORGANIZATION 9,53E-
07
4,70E-04
GO RESPONSE TO RADIATION 1,45E-
06
6,41E-04
GO MRNA METABOLIC PROCESS 1,68E-
06
6,64E-04
GO POSITIVE REGULATION OF RESPONSE TO DNA
DAMAGE STIMULUS
1,80E-
06
6,64E-04
GO RESPONSE TO LIGHT STIMULUS 2,24E-
06
7,64E-04
GO IN UTERO EMBRYONIC DEVELOPMENT 4,09E-
06
1,28E-03
GO NEGATIVE REGULATION OF GENE EXPRESSION 4,55E-
06
1,28E-03
GO DNA GEOMETRIC CHANGE 4,62E-
06
1,28E-03
GO REGULATION OF CELL CYCLE 5,01E-
06
1,31E-03
GO REGULATION OF DNA METABOLIC PROCESS 6,81E-
06
1,68E-03
GO POSITIVE REGULATION OF TRANSCRIPTION FROM
RNA POLYMERASE II PROMOTER
7,87E-
06
1,84E-03
GO REGULATION OF CELLULAR AMIDE METABOLIC
PROCESS
8,56E-
06
1,90E-03
GO REGULATION OF RNA SPLICING 9,47E-
06
2,00E-03
GO DNA DEPENDENT DNA REPLICATION 1,03E-
05
2,07E-03
GO REGULATION OF ALTERNATIVE MRNA SPLICING VIA
SPLICEOSOME
1,48E-
05
2,86E-03
GO POSITIVE REGULATION OF DNA REPAIR 1,91E-
05
3,52E-03
GO REGULATION OF MRNA METABOLIC PROCESS 2,05E-
05
3,64E-03
GO NEGATIVE REGULATION OF CELL CYCLE 2,66E-
05
4,39E-03
GO POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 2,67E-
05
4,39E-03
GO MACROMOLECULE CATABOLIC PROCESS 3,41E-
05
5,24E-03
GO DNA CONFORMATION CHANGE 3,50E-
05
5,24E-03
GO CELL DIVISION 3,73E-
05
5,24E-03
GO PLACENTA DEVELOPMENT 3,79E-
05
5,24E-03
Table 6 (continued )
Gene Set Name p-value FDR q-
value
GO NEGATIVE REGULATION OF CELLULAR COMPONENT
ORGANIZATION
3,80E-
05
5,24E-03
GO MITOTIC CELL CYCLE CHECKPOINT 3,90E-
05
5,24E-03
GO REGULATION OF RESPONSE TO DNA DAMAGE
STIMULUS
4,60E-
05
6,00E-03
GO CELLULAR RESPONSE TO DNA DAMAGE STIMULUS 5,24E-
05
6,64E-03
GO ORGANELLE FISSION 5,65E-
05
6,79E-03
GO REGULATION OF CATABOLIC PROCESS 5,77E-
05
6,79E-03
GO POSITIVE REGULATION OF PEPTIDASE ACTIVITY 5,81E-
05
6,79E-03
GO NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS
DEADENYLATION DEPENDENT DECAY
6,50E-
05
7,39E-03
GO DNA METABOLIC PROCESS 7,23E-
05
8,02E-03
GO LEUKOCYTE HOMEOSTASIS 7,57E-
05
8,19E-03
GO REGULATION OF MRNA SPLICING VIA SPLICEOSOME 8,35E-
05
8,82E-03
GO POSITIVE REGULATION OF CELL CYCLE 8,82E-
05
9,10E-03
GO POSITIVE REGULATION OF GENE EXPRESSION 1,02E-
04
1,02E-02
GO EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG
HATCHING
1,04E-
04
1,02E-02
GO REGULATION OF CELL CYCLE PROCESS 1,08E-
04
1,04E-02
GO CELL CYCLE DNA REPLICATION 1,17E-
04
1,08E-02
GO NEGATIVE REGULATION OF CD4 POSITIVE ALPHA
BETA T CELL DIFFERENTIATION
1,17E-
04
1,08E-02
GO REGULATION OF TRANSCRIPTION FROM RNA
POLYMERASE II PROMOTER
1,29E-
04
1,17E-02
GO IMMUNE SYSTEM DEVELOPMENT 1,35E-
04
1,20E-02
GO REGULATION OF DENDRITE EXTENSION 0,002 0,948
GO POSITIVE REGULATION OF DENDRITE EXTENSION 0,002 0,812
GO RETINOL METABOLIC PROCESS 0,002 0,727
GO METANEPHROS MORPHOGENESIS 0,002 0,731
GO REGULATION OF CILIUM MOVEMENT 0,004 1
GO REGULATION OF OXIDATIVE PHOSPHORYLATION 0,004 0,886
GO TAU PROTEIN BINDING 0,004 0,731
GO E BOX BINDING 0,004 0,758
GO CELLULAR PIGMENT ACCUMULATION 0,004 0,744
GO PIGMENT ACCUMULATION 0,004 0,682
GO MODIFIED AMINO ACID BINDING 0,004 1
GO ISOPRENOID BINDING 0,004 1
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73.3. IFI16 expression is not related to clinical aggressiveness and survival
in MCL
Since IFI16 downregulation appeared to be associated with relevant
cellular function modifications [19, 20, 21, 22, 23, 24, 25, 26, 28], we
investigated whether its expression was associated with clinical fea-
tures. IFI16 gene expression did not significantly differ in indolent (N ¼
7) vs. classical (N ¼ 15) MCL cases (p ¼ 0.67) (Fig. 4A). Similarly, IFI16
gene expression was not associated with overall survival when it was
evaluated as either continuous variable (Cox-regression, p ¼ 0.785), or
by 50th percentiles (p ¼ 0.5, Fig. 4B), or by quartile sub-grouping (p ¼
0.647, Fig. 4C). This was somehow surprising as MCL prognosis is
strictly associated with proliferation [48], which in turn appeared to be
associated with IFI16. However, in CLL the prognostic value of IFI16
reduction was limited to the subgroups of patients presenting with
CD38 and/or ZAP70 expression [30]. Therefore, we cannot exclude that
further investigation in MCL will unveil a prognostic value for this
molecule.
Fig. 4. IFI16 gene expression is not related to clinical aggressiveness and survival in MCL patients. In A, IFI16 gene expression in indolent (N ¼ 7) vs classic (N ¼ 15)
MCL cases; in B, overall survival based on IFI16 gene expression (50 percentiles, high vs low); in C, overall survival based on IFI16 gene expression (quartiles, Q1 the
lowest, Q4 the highest values).
P.P. Piccaluga et al. Heliyon 5 (2019) e026434. Conclusion
In conclusion, we found that IFI16 is significantly downregulated in
MCL, being associated with relevant cellular modifications such as pro-
liferation increase and metabolism activation. Nonetheless the possible
functional value of IFI16 down-regulation remains to be assessed and
further studies need to be performed to determine its real role in MCL.
Similarly, a more extensive evaluation of its prognostic value, in
perspective homogeneous series should be assessed. In fact, our study
was not specifically designed for clinical correlates, the series being not
homogenous and the treatment variable. Finally, the specific potential
impact of IFI16 as a diagnostic marker might be assessed in diagnostic
accuracy study. In fact, though probably not useful for differentiating
MCL from CLL (similarly down regulating it), it might be more relevant
for other differential diagnoses such as, for example, CCND1- MCL vs.
CD5þ DLBCL, in addition to SOX11.
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